New study aims to cut unnecessary prostate biopsies with MRI
NCT ID NCT04993508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to diagnose prostate cancer using PSA tests, digital rectal exams, and MRI scans. Men aged 50-75 with elevated PSA or suspicious exams will get an MRI first. Only those with suspicious MRI results will have a biopsy, and they will be randomly assigned to either MRI-targeted biopsy alone or combined with standard systematic biopsy. The goal is to see if targeted biopsy alone can find serious cancers while avoiding unnecessary detection of low-risk cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could make prostate cancer diagnosis more accurate, reducing unnecessary biopsies and overtreatment.
- What could go wrong
- This is an early-stage study not yet recruiting, and results may not apply to all men or settings. MRI-targeted biopsy might miss some cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?